Chicago - Among patients receiving a novel immune-based maintenance biotherapy regimen (mBT) for metastatic melanoma, those who developed vitiligo had longer median survival.
Amy Spizuoco, DO, FAOCD: Addressing STDs and Utilizing Dermatopathology With Care in Diverse Patient Populations
ReV Up Your Vitiligo Treatment Strategies
Melanoma and the Wrong Site
The Cutaneous Connection: Splish, Splash, AD Management Starts in the Bath
Allergan Aesthetics Launches New Book to Bring More Awareness to Ethics in Aesthetics
Experts Develop Benefit-Risk Conceptual Framework for Biologic Use in Pregnancy